Cantor Fitzgerald Estimates PRQR FY2026 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of ProQR Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the biopharmaceutical company will post earnings per share of ($0.50) for the year. Cantor Fitzgerald has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $4.90 million.

Several other brokerages have also recently weighed in on PRQR. Oppenheimer lowered their target price on ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating for the company in a report on Tuesday, May 13th. HC Wainwright lifted their price objective on ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, March 14th. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Evercore ISI began coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They set an “outperform” rating and a $5.00 target price on the stock. Finally, Chardan Capital restated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR opened at $1.82 on Tuesday. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $4.62. The firm has a market capitalization of $191.49 million, a price-to-earnings ratio of -5.69 and a beta of 0.31. The stock has a 50 day moving average price of $1.53 and a 200 day moving average price of $2.10.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. M&T Bank Corp bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $330,000. Raymond James Financial Inc. acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $260,000. PNC Financial Services Group Inc. purchased a new position in ProQR Therapeutics in the fourth quarter worth $77,000. Platinum Investment Management Ltd. acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $4,076,000. Finally, Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $83,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).